Photo of Stephen E.F. Spurgeon, MD

Stephen E.F. Spurgeon MD

Dr. Spurgeon’s research focuses on translating lab findings into new therapies in chronic lymphocytic leukemia and lymphoma, particularly mantle cell lymphoma.Dr. Spurgeon has a  special interest in: 1) unlocking the importance of cell signaling in lymphoid cancer pathogenesis, 2) identifying new therapeutic targets, 3) developing novel clinical trials, and 4) designing personalized treatment approaches.CLL:  Specifically, he is interested in the role of tyrosine kinases and B cell receptor (BCR) mediated signaling in leukemogenesis in chronic lymphocytic leukemia (CLL). He hopes to develop kinase directed treatment approaches for CLL. He also is interested in determining if in vitro kinase targeted drug screens can help predict in vivo response to anti-leukemic therapy. This includes collaborations with Dr. Marc Loriaux, Dr. Jeffrey Tyner and Dr. Brian Druker in the Center for Cell Signaling.Lymphoma: In collaboration with Dr. Craig Okada at OHSU and Dr. Elliot Epner at Penn State, Dr. Spurgeon is exploring the role of epigenetic therapy in B cell malignancies especially in mantle cell lymphoma. Specifically, he is conducting an early phase clinical trial using cladribine, rituximab and vorniostat in relapsed B cell malignancies and newly diagnosed mantle cell lymphoma and CLL. This study evaluates DNA methylation patterns in patients on therapy and hopes to identify important target genes modified by this combination therapy.


  • M.D., Jefferson Medical College at Thomas Jefferson University, Philadelphia Pennsylvania 2002
  • Residency:

    • 2002-2005, residency: Oregon Health & Science University, Portland, Oregon
  • Fellowship:

    • 2006-2009, fellowship: Oregon Health & Science University, Portland, Oregon
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 2005

Memberships and associations

  • American Society of Oncology


  • "Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib." Cancer In: , Vol. 124, No. 15, 01.08.2018, p. 3192-3200.
  • "Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples." Oncotarget In: , Vol. 9, No. 37, 15.05.2018, p. 24576-24589.
  • "Exaggerated arthropod assault : Eosinophilic dermatosis in a patient with small lymphocytic lymphoma." Clinical Case Reports  In: , 01.01.2018.
  • "Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia." Leukemia and Lymphoma  In: , 19.12.2017, p. 1-3.
  • "SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia." Haematologica In: , Vol. 102, No. 11, 27.10.2017, p. 1890-1900.
  • "Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma." Haematologica In: , Vol. 102, No. 7, 26.06.2017, p. e261-e265.
  • "Obinutuzumab is effective in chronic lymphocytic leukemia and rheumatoid arthritis after rituximab failure : A case report." American Journal of Case Reports  In: , Vol. 18, 10.05.2017, p. 516-519.
  • "Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples." American Journal of Hematology  In: , Vol. 92, No. 5, 01.05.2017, p. E64-E66.
  • "CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation." Leukemia Research In: , Vol. 53, 01.02.2017, p. 39-49.
  • "Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential." American Journal of Hematology In: , Vol. 92, No. 1, 01.01.2017, p. E6-E8.
  • "Recommendations for clinical trial development in mantle cell lymphoma." Journal of the National Cancer Institute In: , Vol. 109, No. 1, djw263, 2017.
  • "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia." Science Translational Medicine In: , Vol. 8, No. 354, 354ra114, 31.08.2016.
  • "Phase 2 study of idelalisib and entospletinib : Pneumonitis limits combination therapy in relapsed refractory CLL and NHL." Blood In: , Vol. 127, No. 20, 19.05.2016, p. 2411-2415.
  • "Survival trends in T cell prolymphocytic leukemia : A SEER database analysis." Leukemia and Lymphoma In: , Vol. 57, No. 4, 02.04.2016, p. 942-944.
  • "Postibrutinib outcomes in patients with mantle cell lymphoma." Blood In: , Vol. 127, No. 12, 24.03.2016, p. 1559-1563.
  • "Cardiac non-Hodgkin's lymphoma : Clinical characteristics and trends in survival." European Journal of Haematology In: , 2016.
  • "Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia." British Journal of Haematology In: , 2016.
  • "MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting." Annals of Hematology  In: , Vol. 94, No. 11, 22.11.2015, p. 1941-1944.
  • "Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells." PLoS One In: , Vol. 10, No. 11, e0143685, 01.11.2015.
  • "Long-term follow-up of MCL patients treated with single-agent ibrutinib : Updated safety and efficacy results." Blood  In: , Vol. 126, No. 6, 06.08.2015, p. 739-745.
  • "Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome." Leukemia Research Reports  In: , Vol. 4, No. 1, 01.01.2015, p. 8-11.
  • "Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients." British Journal of Haematology In: , Vol. 168, No. 1, 01.01.2015, p. 38-45.
  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma." Oncotarget In: , Vol. 6, No. 22, 2015, p. 18921-18932.
  • "Ibrutinib in mantle cell lymphoma patients : Glass half full? Evidence and opinion." Therapeutic Advances in Hematology In: , Vol. 6, No. 5, 2015, p. 242-252.
  • "Aberrations of MYC are a common event in B-cell prolymphocytic leukemia." American Journal of Clinical Pathology  In: , Vol. 142, No. 3, 01.09.2014, p. 347-354.
  • "Chronic lymphocytic leukemia with a FGFR3 translocation : Case report and literature review of an uncommon cytogenetic event." Cancer genetics In: , Vol. 207, No. 7-8, 01.07.2014, p. 340-343.
  • "A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)." Blood In: , Vol. 123, No. 22, 29.05.2014, p. 3398-3405.
  • "Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia." Blood In: , Vol. 123, No. 22, 29.05.2014, p. 3390-3397.
  • "Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma." Blood In: , Vol. 123, No. 22, 29.05.2014, p. 3406-3413.
  • "A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia." Blood In: , Vol. 123, No. 9, 27.02.2014, p. 1302-1308.

Additional information

Edit profile